Tag: alteplase

Tenecteplase shown to be effective for acute ischaemic stroke in large...

In what is claimed to be the largest stroke clinical trial ever run in Canada, researchers have shown that tenecteplase—a safe, well-tolerated drug commonly...

Study findings encourage direct EVT approaches over bridging thrombolysis in select...

A retrospective study involving more than 200 patients has indicated that ‘bridging thrombolysis’ may not be associated with improved functional outcomes in stroke patients...

Preliminary data indicate improved neurological outcomes with alteplase versus placebo

As per early findings from the CHOICE randomised controlled trial (RCT), the use of adjunct, intra-arterial alteplase—among patients with large vessel occlusion (LVO) acute...

Newer clot-busting medication may someday increase time window for stroke treatment

In a phase 2a clinical trial in China, the clot-busting medication tenecteplase has been shown to be effective in restoring blood flow to the...
evt neuroprotection

LINNC 2021: ESCAPE-NEXT trial may bring “dream” of combining neuroprotection with...

At this year’s LINNC Paris Course (14–16 September, Paris, France and virtual), audiences heard that the ESCAPE-NEXT trial (sponsored by NoNO Inc.), which has already started enrolling...

EXTEND-IA TNK Part 2 trial finds no benefit of higher tenecteplase...

With the original trial demonstrating a higher incidence of substantial reperfusion with tenecteplase compared with alteplase prior to endovascular therapy, EXTEND-IA TNK Part 2...
Alteplase

Alteplase at 0.6mg/kg for stroke with unknown time of onset is...

Although an acceptable safety profile was demonstrated for MRI-guided thrombolysis with alteplase at 0.6mg/kg for stroke with unknown time of onset, the latter approach...

Tenecteplase reduces the need for thrombectomy compared to alteplase

Results from the Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) study show that the use of tenecteplase (0.25mg/kg) led to...